Identity
What is GHK-Cu?
A copper(II) complex of the Gly-His-Lys tripeptide, also called copper tripeptide-1.

Research reference · Skin & Collagen
GHK-Cu is the copper complex of the tripeptide glycyl-histidyl-lysine. It is widely studied in skin and wound models and used in topical cosmetics.
Published by Elevated Pharma ·
Identity
A copper(II) complex of the Gly-His-Lys tripeptide, also called copper tripeptide-1.
Research context
Evidence includes laboratory and animal wound studies, gene-expression work and small topical human studies. A 2026 review focuses on copper speciation and formulation quality.
Evidence boundary
Preclinical findings do not establish clinical benefit, and topical findings do not transfer to injected material.
U.S. status · November 7, 2026
FDA removed injectable GHK-Cu from its Category 2 compounding list in April 2026 and scheduled it for advisory-committee review before the end of February 2027. It is not covered by the October 2026 HHS interim policy.
A commentary in Aesthetic Surgery Journal warns that mechanistic plausibility is not clinical validation.
Read the sourceFDA announced the removal of 12 peptide substances from its Category 2 compounding list, effective about April 22, 2026. Removal is not approval.
Read the sourceKey studies
Selected from PubMed: human trials first, then reviews, then foundational laboratory work. Each finding applies to the material and setting studied.
Search all 152 PubMed records for GHK-Cu · Counts and selections checked November 7, 2026.
Reference identifiers
Database identity describes the reference substance, not any specific material or lot.
Official & primary sources
Citation does not imply an Elevated Pharma partnership or endorsement.